FBLG Share Price Performance
US$0.20
-0.75 (-79.31%)
Price US$0.20
Share Pricen/a
FibroBiologics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
FBLG Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
FibroBiologics, Inc. Key Details
About FBLG
- Founded
- 2021
- Employees
- 15
- CEO
- WebsiteView website
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
